Hyperfine

Hyperfine, Inc. is a medical device development company engaged in the development of, MRI solutions and non-invasive neural monitoring technology. The company was founded by Jonathan M. Rothberg on February 25, 2014 and is headquartered in Guilford, CT.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Hyperfine reports Q4 revenue of $1.4M, eyes $14M revenue in 2023

Hyperfine's Q4 2022 earnings call highlighted financial performance, strategic achievements in 2022, challenges in net losses and expenses, and opportunities for revenue growth and expansion in 2023. The company's focus on innovation, partnerships, and commercial progress underpins its outlook for the coming year.

Hyperfine reports record revenue in Q1 2023, eyes U.S. expansion

Hyperfine's Q1 2023 performance reflects strong revenue growth and strategic advancements in FDA clearances and partnerships. While facing significant expenses and cash burn, the company maintains a positive outlook for revenue and growth opportunities through innovation and market expansion.

Hyperfine reports record revenue in Q2 2023 amidst strategic expansion

Hyperfine's Q2 2023 earnings call reflects strong revenue growth, strategic focus on critical care and pediatric markets, and ongoing investment in technology and clinical studies. Despite financial challenges, the company maintains a positive outlook with a clear roadmap for future growth. Managing expenses and cash burn while pursuing innovation will be key to sustainable success.

Hyperfine reports robust Q3 earnings, eyes market expansion opportunities

Hyperfine's Q3 performance showcased strong revenue growth and improved financial metrics.
The company's focus on innovation and collaborations presents opportunities for market expansion.
Challenges include balancing investments in clinical studies while maintaining financial stability.

Hyperfine reports strong revenue growth and innovation focus for 2024

Hyperfine's Q4 2023 performance reflects robust revenue growth, strategic expansion into prestigious institutions, and a focus on cutting-edge healthcare solutions.
While facing financial challenges and a net loss, the company's commitment to innovation, FDA clearances, and market opportunities position it for future success.
With a strong 2024 revenue guidance, Hyperfine is poised to leverage its achievements in 2023, customer success, and international expansion to drive growth and profitability.

Hyperfine reports strong Q1 revenue growth and advances in medical imaging

Hyperfine's Q1 2024 performance reflects revenue growth driven by international contributions and advancements in clinical programs and commercial expansion.
While facing financial challenges and cash burn, the company maintains a positive outlook with plans for future growth and innovation in medical imaging technology.
Strategic strengths in AI software development and clinical applications position Hyperfine well to capture opportunities in the healthcare market and drive revenue growth.

Hyperfine reports robust Q3 growth, eyes international expansion opportunities

Hyperfine's Q3 2024 performance reflects strong revenue growth and operational efficiency improvements.
The company's focus on innovation, clinical efficacy, and market expansion presents opportunities for sustained growth.
However, managing cash burn, meeting revenue targets, and navigating competitive pressures remain key challenges for Hyperfine.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hyperfine, Inc. is a medical device development company, which engages in providing imaging and monitoring through magnetic resonance imaging to revolutionize healthcare for people. It also develops imaging of health conditions through its Swoop portable magnetic resonance. The company was founded by Jonathan M. Rothberg and Ronald Walsworth on February 25, 2014 and is headquartered in Guilford, CT.

GUILFORD, Conn., May 25, 2022 (GLOBE NEWSWIRE) -- Hyperfine (Nasdaq: HYPR), the creator of Swoop®, the world's first FDA-cleared portable MRI system™, today announced that management will be presenting at the upcoming 2022 Jefferies Global Healthcare Conference in New York, New York.

Hyperfine to Present at the 2022 Jefferies Global Healthcare Conference

Hyperfine, Inc. (NASDAQ:HYPR ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Marissa Bych - Gilmartin Group IR Dave Scott - President and CEO Alok Gupta - CFO Conference Call Participants Lawrence Biegelsen - Wells Fargo Vijay Kumar - Evercore ISI Operator Good afternoon, and welcome to Hyperfine's First Quarter 2022 Earnings Conference Call. At this time all participants are in listen-only mode.

Hyperfine, Inc. (HYPR) CEO Dave Scott on Q1 2022 Results - Earnings Call Transcript

GUILFORD, Conn., May 11, 2022 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the creator of Swoop®, the world's first FDA-cleared portable MRI system™, today reported financial results for the quarter ended March 31, 2022. Management will host a corresponding conference call to discuss the financial results and provide a business update today at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Hyperfine Reports First Quarter 2022 Financial Results

GUILFORD, Conn., April 20, 2022 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the creator of Swoop®, the world's first FDA-cleared portable MRI system™, today announced that it will report financial results for the first quarter 2022 on Wednesday, May 11, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Hyperfine to Announce First Quarter 2022 Financial Results on May 11, 2022

Hyperfine, Inc.'s (HYPR) CEO Dave Scott on Q4 2021 Results - Earnings Call Transcript

GUILFORD, Conn., March 23, 2022 (GLOBE NEWSWIRE) -- Hyperfine (Nasdaq: HYPR), the groundbreaking medical device company that created Swoop®, the world's first FDA-cleared portable MRI system™, today announced fourth quarter and full year 2021 financial results and provided a business update.

Hyperfine Reports Fourth Quarter and Full Year 2021 Financial Results

GUILFORD, CT, March 03, 2022 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the creator of Swoop®, the world's first FDA-cleared portable MRI system™, today announced that it will report financial results for the fourth quarter and full year 2021 on Wednesday, March 23, 2022. Company management will host a corresponding conference call to discuss the financial results and provide a business update beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Hyperfine to Announce Fourth Quarter and Full Year 2021 Financial Results

GUILFORD, Conn., March 01, 2022 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the creator of Swoop®, the first FDA-cleared portable magnetic resonance imaging (MRI) system™, today announced that the company will be participating in the upcoming 42nd Annual Cowen Healthcare Conference.

Hyperfine to Present at the 42nd Annual Cowen Healthcare Conference

Creators of the world's first FDA-cleared portable MRI scales executive team for its next phase of development Creators of the world's first FDA-cleared portable MRI scales executive team for its next phase of development

Hyperfine Appoints Chip Truwit, M.D. as Senior Medical Director

World's first FDA-cleared portable MRI expands leading neurosurgery suite's tech capabilities for novel diagnostic and therapeutic approaches World's first FDA-cleared portable MRI expands leading neurosurgery suite's tech capabilities for novel diagnostic and therapeutic approaches

M Health Fairview University of Minnesota Medical Center Receives First Hyperfine Portable MRI to Grow its Advanced Imaging Systems Offering

GUILFORD, Conn., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Hyperfine (Nasdaq: HYPR), the groundbreaking medical device company that created Swoop®, the world's first FDA-cleared portable MRI system™, today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2021.

Hyperfine Reports Preliminary Unaudited 2021 Revenue and Swoop® System Installations

GUILFORD, Conn., Jan. 4, 2022 /PRNewswire/ -- Hyperfine (Nasdaq: HYPR), the groundbreaking medical device company that created Swoop®, the world's first FDA-cleared portable MRI system™, today announced that the company will be participating in the upcoming 40th Annual J.P.

Hyperfine to Present at the 40th Annual J.P. Morgan Healthcare Conference

HealthCor Catalio Acquisition Corp

GUILFORD, Conn., Dec. 22, 2021 /PRNewswire/ -- Hyperfine Inc., the groundbreaking medical device company that created Swoop®, the world's first FDA-cleared portable MRI system™, today announced that it has completed its business combination with HealthCor Catalio Acquisition Corp. (Nasdaq: HCAQ) ("HealthCor"), a special purpose acquisition company sponsored by leading healthcare funds HealthCor Management, L.P.

Hyperfine Closes Business Combination with HealthCor Catalio Acquisition Corp and Liminal Sciences, Will Begin Trading under the Ticker "HYPR" on the Nasdaq Global Market

News for Hyperfine Stock (HYPR)